Related Experiment Video

Updated: May 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic virotherapy needs trials, not access programs

Kevin J Harrington1

  • 1The Institute of Cancer Research, Targeted Therapy Team, London, United Kingdom. Kevin.Harrington@icr.ac.uk

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 4, 2013
PubMed

Insights

Oncolytic virotherapy uses engineered viruses to treat cancer. A Finnish study evaluated an advanced access program for oncolytic adenovirus, detailing its strengths and weaknesses for future research.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Oncolytic virotherapy represents a promising cancer treatment modality.
  • It combines direct tumor cell lysis with immune system activation for antitumor effects.
  • Adenoviruses are a class of viruses being explored for oncolytic applications.

Purpose of the Study:

  • To report on an advanced therapy access program for oncolytic adenovirus in Finland.
  • To analyze the strengths and weaknesses of this access program.
  • To provide insights for the design and conduct of future clinical studies in oncolytic virotherapy.

Main Methods:

  • Retrospective analysis of an advanced therapy access program.
  • Evaluation of clinical data and treatment outcomes.
  • Assessment of program logistics and patient access.

Main Results:

  • The program facilitated access to oncolytic adenovirus therapy.
  • Specific strengths and challenges of the program were identified.
  • Data suggests potential for oncolytic adenovirus in cancer treatment.

Conclusions:

  • Advanced access programs can enable patient access to novel oncolytic virotherapy.
  • Careful consideration of program strengths and weaknesses is crucial for future implementation.
  • Further research is warranted to optimize oncolytic adenovirus therapy and its delivery.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...